Tag Archives: #FDA

FDA OPDP Look Back at 2021 – The Yawning Gap

Once again it was a quiet year with respect to the FDA’s Office of Prescription Drug Programs (OPDP). As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from … Continue reading

Posted in DTC Advertising, FDA, FDA Policy | Tagged , , | Comments Off on FDA OPDP Look Back at 2021 – The Yawning Gap

FDA Authorizes Third Dose – Some Implications

What does “fully vaccinated” mean today? In the face of the widening spread of the SARS-Cov-2 variant, the rise in breakthrough cases, and data that suggests a slight waning effect over time of vaccines, FDA acted yesterday to protect some … Continue reading

Posted in Uncategorized | Tagged , | Comments Off on FDA Authorizes Third Dose – Some Implications

What They Said – FDA Press Releases Mid-2021

It has been a regular feature of the blog to give a read on what FDA has been talking about, at least through the form of press releases. It is not always an easy task because the nature of FDA’s … Continue reading

Posted in FDA, FDA Image | Tagged | Comments Off on What They Said – FDA Press Releases Mid-2021

OPDP Sends Untitled Letter

Upfront Author’s Note: This is the first posting in a while as I have been working to migrate the subscription service to a new provider. As such, some subscribers were lost in the process. Anyone who signed up for a … Continue reading

Posted in Warning Letters | Tagged , , | Comments Off on OPDP Sends Untitled Letter

What They Said – A Look Back at FDA Press Releases First Half of 2020

Each year, midway through it all, I take a look back to see what FDA has been talking about and compare it to the year before to see how things may have changed. I’m a little late at getting to … Continue reading

Posted in FDA Image | Tagged | Comments Off on What They Said – A Look Back at FDA Press Releases First Half of 2020